What is the global market sales and usage of pemetinib?

Pemigatinib, also known as pemigatinib, is an oral targeted drug specifically used to treat patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusion or rearrangement mutations. Since being approved by the U.S. FDA in 2020, pemetinib has been gradually included in clinical use in many countries for patients who still need to control their disease after failure of first-line treatment. As the first approved targeted drug for the treatment of FGFR mutated cholangiocarcinoma, it has filled the gap in treatment methods in this field. Therefore, it has received high attention and rapid clinical application growth in the global market after its launch.

Globally, the main markets for pemetinib include the United States, the European Union, Japan and South Korea, and these countries have generally included the drug in their national or regional cancer treatment guidelines. In the European and American markets, the drug is promoted by Incyte Incyte and has become one of the standard drugs in the treatment of FGFR-positive cholangiocarcinoma. With the popularization of FGFR target detection methods, the number of users of this drug continues to grow. Especially in the context of the lack of effective drug options for the treatment of advanced cholangiocarcinoma, the frequency of its use continues to rise.

In the domestic market, pemetinib is marketed as "pemetinib tablets". Although it has not yet been included in the national medical insurance directory, it has been included in individualized treatment plans by many cancer center hospitals because of its clear curative effect on patients with specific mutation subtypes. At present, the mainstream specifications in the domestic market are 4.5mg14 tablets and 9mg 14 tablets. The price per box ranges from 2 10,000 yuan to 50,000 yuan, which imposes a heavy financial burden on patients, especially if long-term use is required.

It is worth mentioning that generic versions of pemetinib have also appeared in overseas markets, such as 4.5mg*14 tablets produced by Lucius Pharmaceuticals in Laos. Each box is priced at only more than RMB 700, which has become an important reason for some patients to choose to purchase drugs overseas. Although the ingredients of generic drugs are basically the same as those of original drugs, patients should ensure that the source of the drugs is regular and safe before purchasing, and they should be used under the guidance of a professional doctor. Overall, pemetinib is gradually expanding in the global market, but high price is still one of the important factors limiting its popularity.

Reference: https://go.drugbank.com/drugs/